Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dapeng Chen

Showing results (271-280 of 279) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 279 results.
Science Bulletin|January 20, 2023
Pediatric reference intervals in China (PRINCE): design and rationale for a large, multicenter collaborative cross-sectional studyXin Ni, Wenqi Song, Xiaoxia Peng, et al.
Molecular Cancer Therapeutics|December 9, 2024
KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule InhibitorsYogesh K Chutake, Michele F Mayo, Nancy Dumont, et al.
Journal of Medicinal Chemistry|August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune DiseasesXiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Journal of Medicinal Chemistry|April 16, 2019
Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved TolerabilityJoey L Methot, Hua Zhou, Sam D Kattar, et al.
Nature Medicine|November 13, 2023
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trialLindsay Ackerman, Gerard Acloque, Sandro Bacchelli, et al.
Journal of Medicinal Chemistry|April 2, 2021
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ ImmunomodulatorsJoey L Methot, Hua Zhou, Meredeth A McGowan, et al.
Journal of Medicinal Chemistry|October 29, 2021
Discovery of <b>MK-4688</b>: an Efficient Inhibitor of the HDM2-p53 Protein-Protein InteractionMichael H Reutershan, Michelle R Machacek, Michael D Altman, et al.
Journal of Medicinal Chemistry|March 23, 2021
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of CancerRyan V Quiroz, Michael H Reutershan, Sebastian E Schneider, et al.
Respiratory Medicine|October 5, 2024
The impact of the COVID-19 pandemic on RSV outbreaks in children: A multicenter study from ChinaTeng Zhou, Dapeng Chen, Qiang Chen, et al.
Pageof 28

Showing results (271-280 of 279) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 279 results.
Science Bulletin|January 20, 2023
Pediatric reference intervals in China (PRINCE): design and rationale for a large, multicenter collaborative cross-sectional studyXin Ni, Wenqi Song, Xiaoxia Peng, et al.
Molecular Cancer Therapeutics|December 9, 2024
KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule InhibitorsYogesh K Chutake, Michele F Mayo, Nancy Dumont, et al.
Journal of Medicinal Chemistry|August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune DiseasesXiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Journal of Medicinal Chemistry|April 16, 2019
Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved TolerabilityJoey L Methot, Hua Zhou, Sam D Kattar, et al.
Nature Medicine|November 13, 2023
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trialLindsay Ackerman, Gerard Acloque, Sandro Bacchelli, et al.
Journal of Medicinal Chemistry|April 2, 2021
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ ImmunomodulatorsJoey L Methot, Hua Zhou, Meredeth A McGowan, et al.
Journal of Medicinal Chemistry|October 29, 2021
Discovery of <b>MK-4688</b>: an Efficient Inhibitor of the HDM2-p53 Protein-Protein InteractionMichael H Reutershan, Michelle R Machacek, Michael D Altman, et al.
Journal of Medicinal Chemistry|March 23, 2021
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of CancerRyan V Quiroz, Michael H Reutershan, Sebastian E Schneider, et al.
Respiratory Medicine|October 5, 2024
The impact of the COVID-19 pandemic on RSV outbreaks in children: A multicenter study from ChinaTeng Zhou, Dapeng Chen, Qiang Chen, et al.
Pageof 28